Quest Diagnostics Reports 13.1% Revenue Growth to $2.816 Billion in Latest Quarter

Quest Diagnostics Incorporated reported significant financial growth in its latest quarterly results, with net revenues for the three months ended September 30, 2025, reaching $2.816 billion, a 13.1% increase from $2.488 billion in the same period last year. For the nine months ending September 30, 2025, revenues totaled $8.229 billion, up from $7.251 billion, marking a 13.5% year-over-year increase. The company's operating income also saw an increase, rising to $386 million for the third quarter, compared to $330 million in the prior year, while net income attributable to Quest Diagnostics rose to $245 million from $226 million.

The growth in revenue was primarily driven by the Diagnostic Information Services (DIS) segment, which accounted for approximately 97.8% of total revenues. DIS revenues increased by 13.5% year-over-year, attributed to a 12.5% rise in requisition volume and a 0.8% increase in revenue per requisition. The company noted that recent acquisitions contributed significantly to this growth, with the LifeLabs acquisition impacting both revenue and volume metrics. In contrast, revenues from the Diagnostic Solutions (DS) segment remained stable at $61 million, reflecting a slight decline due to lower revenues from risk assessment services.

Operationally, Quest Diagnostics has been focusing on efficiency improvements through its multi-year "Invigorate" program, which aims to achieve annual cost savings of 3% by enhancing productivity across various business areas. The company incurred $37 million in pre-tax charges related to restructuring and integration activities during the nine months ended September 30, 2025. Additionally, the company reported a $29 million impairment charge on long-lived assets related to the exit of a business.

In terms of cash flow, Quest Diagnostics generated $1.421 billion from operating activities in the first nine months of 2025, a substantial increase from $870 million in the same period last year. The company’s cash and cash equivalents stood at $432 million as of September 30, 2025, down from $549 million at the end of 2024. The company also repurchased $150 million worth of its common stock during the nine months, reflecting its commitment to returning value to shareholders.

Looking ahead, Quest Diagnostics anticipates potential impacts from recent healthcare legislation, including the One Big Beautiful Bill Act, which may affect Medicaid funding and regulatory burdens. However, the company does not expect these changes to materially impact its revenues for 2025 and 2026. The management remains optimistic about leveraging its operational efficiencies and strategic acquisitions to sustain growth in the coming quarters.